HOME >> MEDICINE >> NEWS
AMITIZA(TM) (lubiprostone) shown effective and well-tolerated in people older than age 65

AMITIZA(TM) (lubiprostone), the first selective chloride channel activator for the treatment of chronic idiopathic constipation, was effective and well-tolerated in treating the symptoms of chronic idiopathic constipation in the elderly adult population according to findings presented during a poster session today at Digestive Disease Week 2006.

"AMITIZA is unique among prescription treatments for chronic idiopathic constipation, given its novel mechanism of action, which has been shown to provide targeted and predictable relief to people living with this condition," said John Johanson, M.D., clinical associate professor, University of Illinois College of Medicine. "These results further support that AMITIZA may fill an important unmet need for many patients, especially those over age 65, for whom there are limited prescription treatment options currently available to treat chronic idiopathic constipation."

Predictable relief is defined as the ability of study participants to have three spontaneous bowel movements or more per week.

Constipation is one of the most common digestive complaints, affecting more than 30 million Americans, and is especially prevalent in adults over the age of 65. It is the cause of 2.5 million visits to physicians and 92,000 hospitalizations annually. AMITIZA is the only prescription medication for chronic idiopathic constipation that can be used in people age 65+ for longer than two weeks. Approximately one of four patients over 65 suffers from chronic constipation, a condition that increases with age-related bowel changes.

AMITIZA, approved by the U.S. Food and Drug Administration (FDA) in January 2006, is an oral treatment that works by increasing fluid secretion in the small intestine by activating ClC-2 chloride channels, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation. AMITIZA was developed by Sucampo Pharmaceuticals, Inc., an
'"/>

Contact: Jocelyn M. Gerst
847-383-3696
Ketchum
22-May-2006


Page: 1 2

Related medicine news :

1. New study demonstrates that AMITIZA (lubiprostone) may help improve symptoms
2. AMITIZA (lubiprostone) launches in the United States
3. Pro-vitamin E shown to be active against breast cancer cells
4. Ultra low-dose estrogen shown safe for post-menopausal women
5. ROZEREM (ramelteon) shown to be effective in a first-night-effect model of transient
6. Radiation therapy shown to increase survival in certain lung cancer patients
7. Drug shown to provide much needed alternative therapy for chronic shoulder pain
8. Nexium shown to reduce gastric ulcers in at-risk patients using long-term NSAIDS
9. State board-disciplined physicians more likely to have shown unprofessional behavior in med school
10. Technology for successful aging shown at White House conference
11. Stress echo tests shown to predict cardiac death, illness in higher-risk women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/20/2019)... ... March 20, 2019 , ... Capio®, the leading provider of ... to 2018. In total, sales generated for 2018 were the highest ever for ... significant accomplishments and milestones in 2018. In addition to achieving record sales and ...
(Date:3/20/2019)... ... March 20, 2019 , ... VirtuOx, ... a new way to diagnose cardiac arrhythmias in the patient’s home. , The ... by utilizing mobile cardiac telemetry (MCT) in the convenience and comfort of the ...
(Date:3/20/2019)... ... March 20, 2019 , ... cbdMD, a Level ... – Mingo Rad. , Mingo Rad dedicates its resources to offering superior ... with a unique manufacturing process, Mingo Rad offers as non-GMO, gluten- and THC-free ...
(Date:3/20/2019)... ... 20, 2019 , ... Adam Equipment, a leading provider of professional balances worldwide, ... from 26-28 March at Paris expo Porte de Versailles in France. , During the ... series of balances. Both balance lines include models that deliver two to five places ...
(Date:3/19/2019)... Pa. (PRWEB) , ... March 19, 2019 , ... The ... team with the hiring of industry expert William Mencia, M.D., FACEHP, CHCP. Dr. ... Prova Education , Omnia Education , Medtelligence , and AGILE ...
Breaking Medicine News(10 mins):
(Date:3/20/2019)... (PRWEB) , ... March 20, ... ... digital marketplace for outsourced research services and products, announced today that it ... of HEOR services. The Canadian-based company offers RWE research, systematic literature review, ...
(Date:3/20/2019)... ... March 20, 2019 , ... NDA Partners Chairman ... with extensive experience in the development of generic drugs and drug/device combination products at ... as an Expert Consultant. , During his career with FDA, Mr. Gonitzke served as ...
(Date:3/19/2019)... , ... March 19, 2019 , ... TreTap Launches First-Ever ... during two week online contest – One winner will receive TreTap beverages for a ... first ever CBD infused maple water beverage. Tretap, which was acquired by Vermont’s original ...
Breaking Medicine Technology:
Cached News: